

Jan-Willem C Alffenaar

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/814848/jan-willem-c-alfenaar-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

264
papers

5,855
citations

41
h-index

63
g-index

285
ext. papers

7,688
ext. citations

7.6
avg, IF

5.9
L-index

#	Paper	IF	Citations
264	Digital Health Technologies to Improve Medication Adherence and Treatment Outcomes in Patients With Tuberculosis: Systematic Review of Randomized Controlled Trials.. <i>Journal of Medical Internet Research</i> , 2022 , 24, e33062	7.6	3
263	Paediatric Acute Respiratory Distress Syndrome Neuromuscular Blockade study (PAN-study): a phase IV randomised controlled trial of early neuromuscular blockade in moderate-to-severe paediatric acute respiratory distress syndrome.. <i>Trials</i> , 2022 , 23, 96	2.8	
262	Real-World Effects of Antibiotic Treatment on Acute COPD Exacerbations in Outpatients: A Cohort Study under the PharmLines Initiative.. <i>Respiration</i> , 2022 , 1-12	3.7	
261	Dosing of vancomycin and target attainment in neonates: a systematic review.. <i>International Journal of Antimicrobial Agents</i> , 2022 , 106515	14.3	0
260	Practices of therapeutic drug monitoring in tuberculosis - an international survey.. <i>European Respiratory Journal</i> , 2022 ,	13.6	0
259	Standard ganciclovir dosing results in slow decline of cytomegalovirus viral loads.. <i>Journal of Antimicrobial Chemotherapy</i> , 2022 , 77, 466-473	5.1	0
258	Barriers to Optimal Tuberculosis Treatment Services at Community Health Centers: A Qualitative Study From a High Prevalent Tuberculosis Country.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 857783	5.6	0
257	Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP).. <i>BMJ Open</i> , 2022 , 12, e054788	3	0
256	Country-specific lockdown measures in response to the COVID-19 pandemic and its impact on tuberculosis control: a global study.. <i>Jornal Brasileiro De Pneumologia</i> , 2022 , 48, e20220087	1.1	1
255	Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy and haemopoietic stem cell transplant recipients, 2021.. <i>Internal Medicine Journal</i> , 2021 , 51 Suppl 7, 37-66	1.6	11
254	Barriers and strategies to successful tuberculosis treatment in a high-burden tuberculosis setting: a qualitative study from the patient's perspective. <i>BMC Public Health</i> , 2021 , 21, 1903	4.1	4
253	Clinical relevance of rifampicin-moxifloxacin interaction in isoniazid resistant/intolerant tuberculosis patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , AAC0182921	5.9	0
252	Therapeutic drug monitoring of ganciclovir: where are we?. <i>Therapeutic Drug Monitoring</i> , 2021 , 44,	3.2	2
251	Therapeutic Drug Monitoring of the Echinocandin Antifungal Agents: Is There a Role in Clinical Practice? A Position Statement of the Anti-Infective Drugs Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. <i>Therapeutic Drug Monitoring</i> , 2021 ,	3.2	2
250	Drug Exposure and Minimum Inhibitory Concentration Predict Pulmonary Tuberculosis Treatment Response. <i>Clinical Infectious Diseases</i> , 2021 , 73, e3520-e3528	11.6	7
249	Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 685-710	6.2	8
248	Mycobacterium tuberculosis sterilizing activity of faropenem, pyrazinamide and linezolid combination and failure to shorten the therapy duration. <i>International Journal of Infectious Diseases</i> , 2021 , 104, 680-684	10.5	1

247	Levofloxacin pharmacokinetics in saliva as measured by a mobile microvolume UV spectrophotometer among people treated for rifampicin-resistant TB in Tanzania. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 1547-1552	5.1	4
246	Therapeutic Drug Monitoring in Non-Tuberculosis Mycobacteria Infections. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 711-725	6.2	2
245	From Therapeutic Drug Monitoring to Model-Informed Precision Dosing for Antibiotics. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 109, 928-941	6.1	30
244	Predictive Performance of Bayesian Vancomycin Monitoring in the Critically Ill. <i>Critical Care Medicine</i> , 2021 , 49, e952-e960	1.4	3
243	Protocol for establishing an Adaptive Diseases control Expert Programme in Tanzania (ADEPT) for integrating care of communicable and non-communicable diseases using tuberculosis and diabetes as a case study. <i>BMJ Open</i> , 2021 , 11, e041521	3	4
242	Investigator-Initiated Studies in Infectious Diseases-Considerations for Pharmacokinetic-Pharmacodynamic Optimization. <i>Clinical Infectious Diseases</i> , 2021 , 73, 1742	11.6	
241	Combined Impact of Inflammation and Pharmacogenomic Variants on Voriconazole Trough Concentrations: A Meta-Analysis of Individual Data. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
240	Reply to Van Daele et al., "Fluconazole Underexposure in Critically Ill Patients: a Matter of Using the Right Targets?". <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65,	5.9	1
239	Cefdinir and β -Lactamase Inhibitor Independent Efficacy Against. <i>Frontiers in Pharmacology</i> , 2021 , 12, 677005	5.6	3
238	Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis. <i>Archives of Disease in Childhood</i> , 2021 ,	2.2	7
237	Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China. <i>European Respiratory Journal</i> , 2021 , 57,	13.6	3
236	Therapeutic drug monitoring in patients with tuberculosis and concurrent medical problems. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021 , 17, 23-39	5.5	6
235	Drug exposure of first-line anti-tuberculosis drugs in China: A prospective pharmacological cohort study. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 1347-1358	3.8	3
234	A mobile microvolume UV/visible light spectrophotometer for the measurement of levofloxacin in saliva. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 423-429	5.1	5
233	Therapeutic drug monitoring practice in patients with active tuberculosis: assessment of opportunities. <i>European Respiratory Journal</i> , 2021 , 57,	13.6	2
232	Alternative Sampling Devices to Collect Dried Blood Microsamples: State-of-the-Art. <i>Therapeutic Drug Monitoring</i> , 2021 , 43, 310-321	3.2	8
231	A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 943-953	6.2	1
230	Optimization of Fluconazole Dosing for the Prevention and Treatment of Invasive Candidiasis Based on the Pharmacokinetics of Fluconazole in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65,	5.9	4

229	Saliva-based linezolid monitoring on a mobile UV spectrophotometer. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 1786-1792	5.1	1
228	Emerging therapeutic drug monitoring of anti-infective agents in Australian hospitals: Availability, performance and barriers to implementation. <i>British Journal of Clinical Pharmacology</i> , 2021 ,	3.8	6
227	Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study. <i>European Respiratory Journal</i> , 2021 , 58,	13.6	17
226	Assessment of cefepime toxicodynamics: comprehensive examination of pharmacokinetic/pharmacodynamic targets for cefepime-induced neurotoxicity and evaluation of current dosing guidelines. <i>International Journal of Antimicrobial Agents</i> , 2021 , 58, 106443	14.3	3
225	Monitoring Treatment: Clinical and Programmatic Approach for Drug-Susceptible and Drug-Resistant Tuberculosis 2021 , 163-170		
224	Malnutrition assessment methods in adult patients with tuberculosis: a systematic review.. <i>BMJ Open</i> , 2021 , 11, e049777	3	0
223	A simple HPLC-UV Method for Therapeutic Drug Monitoring of Linezolid in human Plasma in low-resourced settings. <i>Journal of Applied Bioanalysis</i> , 2021 , 7, e21008-e21008	1.3	1
222	Optimal Dose or Optimal Exposure? Consideration for Linezolid in Tuberculosis Treatment. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	1
221	Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. <i>Intensive Care Medicine</i> , 2020 , 46, 1127-1153	14.5	184
220	Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid. <i>European Respiratory Journal</i> , 2020 , 56,	13.6	3
219	Exploring failure of antimicrobial prophylaxis and pre-emptive therapy for transplant recipients: a systematic review. <i>BMJ Open</i> , 2020 , 10, e034940	3	
218	Interventions to improve medication adherence in tuberculosis patients: a systematic review of randomized controlled studies. <i>Npj Primary Care Respiratory Medicine</i> , 2020 , 30, 21	3.2	21
217	Towards elimination of childhood and adolescent tuberculosis in the Netherlands: an epidemiological time-series analysis of national surveillance data. <i>European Respiratory Journal</i> , 2020 , 56,	13.6	1
216	Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. <i>European Respiratory Journal</i> , 2020 , 56,	13.6	147
215	Delamanid Resistance: Update and Clinical Management. <i>Clinical Infectious Diseases</i> , 2020 , 71, 3252-3259	11.6	7
214	Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a prospective multicentre cohort study. <i>BMJ Open</i> , 2020 , 10, e035350	3	0
213	Challenging the management of drug-resistant tuberculosis. <i>Lancet, The</i> , 2020 , 395, 783	4.0	8
212	Saliva for Precision Dosing of Antifungal Drugs: Saliva Population PK Model for Voriconazole Based on a Systematic Review. <i>Frontiers in Pharmacology</i> , 2020 , 11, 894	5.6	2

211	Epidemic and pandemic viral infections: impact on tuberculosis and the lung: A consensus by the World Association for Infectious Diseases and Immunological Disorders (WAidid), Global Tuberculosis Network (GTN), and members of the European Society of Clinical Microbiology and Infectious Diseases Study Group for Mycobacterial Infections (ESCMYO). <i>European Respiratory Journal</i> , 2020 , 56	13.6	42
210	Pharmacokinetic Modeling, Simulation, and Development of a Limited Sampling Strategy of Cycloserine in Patients with Multidrug-/Extensively Drug-Resistant Tuberculosis. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 899-910	6.2	7
209	Evaluation of target attainment of oral posaconazole suspension in immunocompromised children. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 726-729	5.1	5
208	Precision and personalized medicine and anti-TB treatment: Is TDM feasible for programmatic use?. <i>International Journal of Infectious Diseases</i> , 2020 , 92S, S5-S9	10.5	7
207	Therapeutic drug monitoring using saliva as matrix: an opportunity for linezolid, but challenge for moxifloxacin. <i>European Respiratory Journal</i> , 2020 , 55,	13.6	7
206	MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. <i>International Journal of Infectious Diseases</i> , 2020 , 92S, S15-S25	10.5	59
205	Repurposed Oral Ribavirin for Respiratory Virus Infections Requires Pharmacokinetic-pharmacodynamic Dose Optimization. <i>Clinical Infectious Diseases</i> , 2020 , 70, 1258	11.6	1
204	Continuous versus intermittent infusion of cefotaxime in critically ill patients: a randomized controlled trial comparing plasma concentrations. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 441-448	5.1	2
203	Evaluation of 10 years of parainfluenza virus, human metapneumovirus, and respiratory syncytial virus infections in lung transplant recipients. <i>American Journal of Transplantation</i> , 2020 , 20, 3529-3537	8.7	5
202	Cross-validation of Liquid Chromatography-Tandem Mass Spectrometry Method for Quantification of Levofloxacin in Saliva. <i>Journal of Applied Bioanalysis</i> , 2020 , 6, 68-70	1.3	2
201	Influence of age on real-life effects of doxycycline for acute exacerbations among COPD outpatients: a population-based cohort study. <i>BMJ Open Respiratory Research</i> , 2020 , 7,	5.6	1
200	Patients and Medical Staff Attitudes Toward the Future Inclusion of eHealth in Tuberculosis Management: Perspectives From Six Countries Evaluated using a Qualitative Framework. <i>JMIR MHealth and UHealth</i> , 2020 , 8, e18156	5.5	1
199	A snapshot of exhaled nitric oxide and asthma characteristics: experience from high to low income countries. <i>Pulmonology</i> , 2020 ,	3.7	4
198	Should we worry about bedaquiline exposure in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis?. <i>European Respiratory Journal</i> , 2020 , 55,	13.6	6
197	Therapeutic Drug Monitoring Can Improve Linezolid Dosing Regimens in Current Clinical Practice: A Review of Linezolid Pharmacokinetics and Pharmacodynamics. <i>Therapeutic Drug Monitoring</i> , 2020 , 42, 83-92	3.2	21
196	Therapeutic drug monitoring of commonly used anti-infective agents: A nationwide cross-sectional survey of Australian hospital practices. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106180	14.3	8
195	Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January-April 2020. <i>Emerging Infectious Diseases</i> , 2020 , 26, 2709-2712	10.2	55
194	Caspofungin Weight-Based Dosing Supported by a Population Pharmacokinetic Model in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	7

193	Coronavirus Disease-19: An Interim Evidence Synthesis of the World Association for Infectious Diseases and Immunological Disorders (Waidid). <i>Frontiers in Medicine</i> , 2020 , 7, 572485	4.9	10
192	Development and validation of a simple LC-MS/MS method for simultaneous determination of moxifloxacin, levofloxacin, prothionamide, pyrazinamide and ethambutol in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2020 , 1158, 122397	3.2	4
191	Treatment outcomes of patients with MDR-TB in Nepal on a current programmatic standardised regimen: retrospective single-centre study. <i>BMJ Open Respiratory Research</i> , 2020 , 7,	5.6	3
190	Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End Tuberculosis. <i>Clinical Infectious Diseases</i> , 2020 , 70, 1774-1780	11.6	32
189	Respiratory Syncytial Virus Infection Morbidity in the Elderly: Time for Repurposing of Ribavirin?. <i>Clinical Infectious Diseases</i> , 2020 , 70, 2238-2239	11.6	1
188	Improving antibacterial prescribing safety in the management of COPD exacerbations: systematic review of observational and clinical studies on potential drug interactions associated with frequently prescribed antibacterials among COPD patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 2218-2224	5.1	4
187	Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations. <i>Mycoses</i> , 2019 , 62, 698-705	5.2	14
186	Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study. <i>International Journal of Infectious Diseases</i> , 2019 , 83, 72-76	10.5	32
185	Limited Sampling Strategies Using Linear Regression and the Bayesian Approach for Therapeutic Drug Monitoring of Moxifloxacin in Tuberculosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	12
184	Optimal Sampling Strategies for Therapeutic Drug Monitoring of First-Line Tuberculosis Drugs in Patients with Tuberculosis. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 1445-1454	6.2	10
183	Reduced moxifloxacin exposure in patients with tuberculosis and diabetes. <i>European Respiratory Journal</i> , 2019 , 54,	13.6	4
182	Acquired Drug Resistance: Recognizing the Potential of Repurposed Drugs. <i>Clinical Infectious Diseases</i> , 2019 , 69, 2038-2039	11.6	3
181	A volumetric absorptive microsampling LC-MS/MS method for five immunosuppressants and their hematocrit effects. <i>Bioanalysis</i> , 2019 , 11, 495-508	2.1	18
180	Tuberculosis-Related Malnutrition: Public Health Implications. <i>Journal of Infectious Diseases</i> , 2019 , 220, 340-341	7	6
179	Diabetes mellitus comorbidity in patients enrolled in tuberculosis drug efficacy trials around the world: A systematic review. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 1407-1417	3.8	7
178	Comment on: The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 834	5.1	1
177	Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery. <i>Journal of Infection</i> , 2019 , 78, 35-39	18.9	21
176	Performance of a web-based application measuring spot quality in dried blood spot sampling. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019 , 57, 1846-1853	5.9	4

175	In vitro evaluation of an intravenous microdialysis catheter for therapeutic drug monitoring of gentamicin and vancomycin. <i>Pharmacology Research and Perspectives</i> , 2019 , 7, e00483	3.1	4
174	Management of patients with multidrug-resistant tuberculosis. <i>International Journal of Tuberculosis and Lung Disease</i> , 2019 , 23, 645-662	2.1	33
173	Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. <i>European Respiratory Journal</i> , 2019 , 54,	13.6	64
172	Evaluation of Saliva as a Potential Alternative Sampling Matrix for Therapeutic Drug Monitoring of Levofloxacin in Patients with Multidrug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	13
171	Nationwide analysis of treatment outcomes in children and adolescents routinely treated for tuberculosis in the Netherlands. <i>European Respiratory Journal</i> , 2019 , 54,	13.6	6
170	Clinical application of a dried blood spot assay for sirolimus and everolimus in transplant patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019 , 57, 1854-1862	5.9	6
169	Darunavir Population Pharmacokinetic Model Based on HIV Outpatient Data. <i>Therapeutic Drug Monitoring</i> , 2019 , 41, 59-65	3.2	4
168	Quality Assessment of Dried Blood Spots from Patients With Tuberculosis from 4 Countries. <i>Therapeutic Drug Monitoring</i> , 2019 , 41, 714-718	3.2	7
167	Official International Association for Therapeutic Drug Monitoring and Clinical Toxicology Guideline: Development and Validation of Dried Blood Spot-Based Methods for Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2019 , 41, 409-430	3.2	91
166	Treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring: first experiences with sub-300 mg linezolid dosages using in-house made capsules. <i>European Respiratory Journal</i> , 2019 , 54,	13.6	13
165	Nontuberculosis mycobacteria infections: would there be pharmacodynamics without pharmacokinetics?. <i>European Respiratory Journal</i> , 2019 , 54,	13.6	3
164	1538. Who Will Benefit From Therapeutic Drug Monitoring of Ganciclovir?. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S560-S561	1	78
163	Therapeutic Drug Monitoring: The Need for Practical Guidance. <i>Clinical Infectious Diseases</i> , 2019 , 68, 1065-1066	11.6	16
162	Population pharmacokinetics of ribavirin in lung transplant recipients and examination of current and alternative dosing regimens. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 691-698	5.1	2
161	A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 747-766	6.2	29
160	Regimen design and pharmacokinetic-pharmacodynamic science: lessons learned. <i>Lancet Infectious Diseases</i> , 2019 , 19, 3-4	25.5	
159	Role of Therapeutic Drug Monitoring in Treatment Optimization in Tuberculosis and Diabetes Mellitus Comorbidity. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	5
158	Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	13

157	The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019. <i>Drugs</i> , 2019 , 79, 161-171	12.1	39
156	Levofloxacin pharmacokinetics, pharmacodynamics and outcome in multidrug-resistant tuberculosis patients. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	8
155	Posaconazole trough concentrations are not influenced by inflammation: A prospective study. <i>International Journal of Antimicrobial Agents</i> , 2019 , 53, 325-329	14.3	7
154	Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs.. <i>Clinical Mass Spectrometry</i> , 2019 , 14 Pt A, 34-45	1.9	7
153	Antituberculosis Drug-induced Liver Injury in Children: Incidence and Risk Factors During the Two-month Intensive Phase of Therapy. <i>Pediatric Infectious Disease Journal</i> , 2019 , 38, 50-53	3.4	6
152	Predictors for treatment outcomes among patients with drug-susceptible tuberculosis in the Netherlands: a retrospective cohort study. <i>Clinical Microbiology and Infection</i> , 2019 , 25, 761.e1-761.e7	9.5	10
151	Pharmacokinetics of 2,000 Milligram Ertapenem in Tuberculosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	7
150	Lack of penetration of amikacin into saliva of tuberculosis patients. <i>European Respiratory Journal</i> , 2018 , 51,	13.6	6
149	Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2018 , 51,	13.6	5
148	Pound foolish and penny wise-when will dosing of rifampicin be optimised?. <i>Lancet Respiratory Medicine</i> , 2018 , 6, e11-e12	35.1	8
147	Susceptibility of Mycobacterium tuberculosis to Amikacin, Kanamycin, and Capreomycin. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	11
146	Bedaquiline Resistance: Its Emergence, Mechanism, and Prevention. <i>Clinical Infectious Diseases</i> , 2018 , 66, 1625-1630	11.6	72
145	Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs. <i>Clinical Infectious Diseases</i> , 2018 , 67, 1743-1749	11.6	16
144	Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 2305-2313	5.1	42
143	Renal Fanconi syndrome with meropenem-containing regimen in drug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2018 , 51,	13.6	
142	Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 1755-1762	5.1	19
141	Risk factors contributing to a low darunavir plasma concentration. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 456-461	3.8	4
140	Antifungal PK/PD in the Critically Ill 2018 , 213-238		

139	The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 2747-2760 ^{3,8} ²⁹		
138	Invasive Candidiasis in the Elderly: Considerations for Drug Therapy. <i>Drugs and Aging</i> , 2018 , 35, 781-789	4.7	10
137	Assessment of the Additional Value of Verapamil to a Moxifloxacin and Linezolid Combination Regimen in a Murine Tuberculosis Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	4
136	Evaluation of dried blood spot sampling for pharmacokinetic research and therapeutic drug monitoring of anti-tuberculosis drugs in children. <i>International Journal of Antimicrobial Agents</i> , 2018 , 52, 109-113	14.3	9
135	Cost-utility analysis of high-dose treatment for intermediate-susceptible, dose-dependent tuberculosis patients. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018 , 22, 991-999	2.1	
134	Simple and robust LC-MS/MS analysis method for therapeutic drug monitoring of micafungin. <i>Bioanalysis</i> , 2018 , 10, 877-886	2.1	7
133	Determination of levofloxacin in human serum using liquid chromatography tandem mass spectrometry. <i>Journal of Applied Bioanalysis</i> , 2018 , 4, 16-25	1.3	6
132	Polymorphisms of NAT2, CYP2E1, GST, and HLA related to drug-induced liver injury in Indonesian tuberculosis patients. <i>International Journal of Mycobacteriology</i> , 2018 , 7, 380-386	0.9	9
131	New Approaches and Therapeutic Options for Mycobacterium tuberculosis in a Dormant State. <i>Clinical Microbiology Reviews</i> , 2018 , 31,	34	44
130	Systematic Review of Salivary Versus Blood Concentrations of Antituberculosis Drugs and Their Potential for Salivary Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2018 , 40, 17-37	3.2	22
129	Linezolid-based Regimens for Multidrug-resistant Tuberculosis (TB): A Systematic Review to Establish or Revise the Current Recommended Dose for TB Treatment. <i>Clinical Infectious Diseases</i> , 2018 , 67, S327-S335	11.6	31
128	Pharmacokinetic/Pharmacodynamic Background and Methods and Scientific Evidence Base for Dosing of Second-line Tuberculosis Drugs. <i>Clinical Infectious Diseases</i> , 2018 , 67, S267-S273	11.6	20
127	d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal. <i>Clinical Infectious Diseases</i> , 2018 , 67, S308-S316	11.6	26
126	Amikacin Dosing for MDR Tuberculosis: A Systematic Review to Establish or Revise the Current Recommended Dose for Tuberculosis Treatment. <i>Clinical Infectious Diseases</i> , 2018 , 67, S303-S307	11.6	21
125	Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study. <i>BMJ Open</i> , 2018 , 8, e023899	3	5
124	Risk factors of multidrug-resistant tuberculosis: A global systematic review and meta-analysis. <i>Journal of Infection</i> , 2018 , 77, 469-478	18.9	52
123	Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	18
122	Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. <i>Lancet, The</i> , 2018 , 392, 821-834	40	281

121	Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	35
120	Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	9
119	Target attainment with continuous dosing of piperacillin/tazobactam in critical illness: a prospective observational study. <i>International Journal of Antimicrobial Agents</i> , 2017 , 50, 68-73	14.3	10
118	Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	18
117	Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. <i>European Respiratory Journal</i> , 2017 , 49,	13.6	142
116	Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis. <i>European Respiratory Journal</i> , 2017 , 49,	13.6	12
115	Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2017 , 49,	13.6	14
114	Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2017 , 49,	13.6	12
113	Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis. <i>International Journal of Antimicrobial Agents</i> , 2017 , 49, 688-694	14.3	24
112	Dried blood spot validation of five immunosuppressants, without hematocrit correction, on two LC-MS/MS systems. <i>Bioanalysis</i> , 2017 , 9, 553-563	2.1	27
111	Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	21
110	Multidrug-resistant tuberculosis: pharmacokinetic and pharmacodynamic science. <i>Lancet Infectious Diseases</i> , 2017 , 17, 898	25.5	6
109	Food intake and darunavir plasma concentrations in people living with HIV in an outpatient setting. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 2325-2329	3.8	5
108	Flucloxacillin Results in Suboptimal Plasma Voriconazole Concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	13
107	Membrane Filtration Is Suitable for Reliable Elimination of Mycobacterium tuberculosis from Saliva for Therapeutic Drug Monitoring. <i>Journal of Clinical Microbiology</i> , 2017 , 55, 3292-3293	9.7	10
106	Sterilizing Effect of Ertapenem-Clavulanate in a Hollow-Fiber Model of Tuberculosis and Implications on Clinical Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	20
105	Clinical Validation of Simultaneous Analysis of Tacrolimus, Cyclosporine A, and Creatinine in Dried Blood Spots in Kidney Transplant Patients. <i>Transplantation</i> , 2017 , 101, 1727-1733	1.8	24
104	Low Caspofungin Exposure in Patients in Intensive Care Units. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	29

103	Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers. <i>Expert Review of Anti-Infective Therapy</i> , 2017 , 15, 11-21	5.5	16
102	Voriconazole metabolism is influenced by severe inflammation: a prospective study. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 261-267	5.1	73
101	Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians. <i>Clinical Infectious Diseases</i> , 2017 , 64, 104-105	11.6	27
100	Bioavailability of voriconazole in hospitalised patients. <i>International Journal of Antimicrobial Agents</i> , 2017 , 49, 243-246	14.3	10
99	The effect of inflammation on voriconazole trough concentrations in children. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 678-680	3.8	9
98	Treatment of Mycobacterium avium-intracellulare complex: a great leap forward. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, i1-i2	5.1	1
97	Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis. <i>Emerging Infectious Diseases</i> , 2017 , 23,	10.2	34
96	Pharmacokinetics of Bedaquiline in Cerebrospinal Fluid and Serum in Multidrug-Resistant Tuberculous Meningitis. <i>Clinical Infectious Diseases</i> , 2016 , 62, 523-4	11.6	23
95	Dosage of isoniazid and rifampicin poorly predicts drug exposure in tuberculosis patients. <i>European Respiratory Journal</i> , 2016 , 48, 1237-1239	13.6	7
94	Sertraline for HIV-associated cryptococcal meningitis. <i>Lancet Infectious Diseases, The</i> , 2016 , 16, 1111	25.5	2
93	Comment on: Utility of voriconazole therapeutic drug monitoring: a meta-analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 3316-3317	5.1	6
92	Statin Adjunctive Therapy for Tuberculosis Treatment. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 7004	5.9	7
91	Therapeutic Drug Monitoring of Posaconazole: an Update. <i>Current Fungal Infection Reports</i> , 2016 , 10, 51-61	1.4	99
90	Dried blood spots can help decrease the burden on patients dually infected with multidrug-resistant tuberculosis and HIV. <i>European Respiratory Journal</i> , 2016 , 48, 932-4	13.6	6
89	Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 1025-37	3.8	15
88	Reply to Verhaeghe et al. <i>Clinical Infectious Diseases</i> , 2016 , 63, 146-7	11.6	
87	Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 703-10	5.1	25
86	Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016 , 12, 533-44	5.5	39

85	Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics. <i>European Respiratory Journal</i> , 2016 , 47, 1867-9	13.6	46
84	Longitudinal Analysis of the Effect of Inflammation on Voriconazole Trough Concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 2727-31	5.9	38
83	LC-MS/MS for Therapeutic Drug Monitoring of anti-infective drugs. <i>TrAC - Trends in Analytical Chemistry</i> , 2016 , 84, 34-40	14.6	36
82	Emerging drugs and alternative possibilities in the treatment of tuberculosis. <i>Expert Opinion on Emerging Drugs</i> , 2016 , 21, 103-16	3.7	11
81	End TB with precision treatment!. <i>European Respiratory Journal</i> , 2016 , 47, 680-2	13.6	36
80	Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016 , 12, 509-21	5.5	46
79	Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2016 , 47, 1229-34	13.6	26
78	Therapeutic drug monitoring of first-line anti-tuberculosis drugs comprises more than C2h measurements. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016 , 20, 1695-1696	2.1	1
77	Alternative Sampling Strategies for Therapeutic Drug Monitoring 2016 , 279-336		11
76	Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis Patients. <i>PLoS ONE</i> , 2016 , 11, e0149768	3.7	20
75	Predictors of Prolonged TB Treatment in a Dutch Outpatient Setting. <i>PLoS ONE</i> , 2016 , 11, e0166030	3.7	5
74	Immunoassay Analysis of Kanamycin in Serum Using the Tobramycin Kit. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 4646-51	5.9	10
73	Shorter treatment for multidrug-resistant tuberculosis: the good, the bad and the ugly. <i>European Respiratory Journal</i> , 2016 , 48, 1800-1802	13.6	9
72	Pharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 2691-703	5.1	25
71	Is there still room for therapeutic drug monitoring of linezolid in patients with tuberculosis?. <i>European Respiratory Journal</i> , 2016 , 47, 1288-90	13.6	10
70	Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 3942-7	5.9	6
69	Susceptibility Testing of Antibiotics That Degrade Faster than the Doubling Time of Slow-Growing Mycobacteria: Ertapenem Sterilizing Effect versus Mycobacterium tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 3193-5	5.9	16
68	Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 2336-42	5.9	25

67	Fixed-dose combination and therapeutic drug monitoring in tuberculosis: friend or foe?. <i>European Respiratory Journal</i> , 2016 , 48, 1230-1233	13.6	4
66	Individualized treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring. <i>International Journal of Mycobacteriology</i> , 2016 , 5 Suppl 1, S44-S45	0.9	7
65	Acquired drug resistance: we can do more than we think!. <i>Clinical Infectious Diseases</i> , 2015 , 60, 969-70	11.6	15
64	Dried blood spot analysis of creatinine with LC-MS/MS in addition to immunosuppressants analysis. <i>Analytical and Bioanalytical Chemistry</i> , 2015 , 407, 1585-94	4.4	32
63	Breakpoints and drug exposure are inevitably closely linked. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 1384	5.9	4
62	Determination of bedaquiline in human serum using liquid chromatography-tandem mass spectrometry. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 5675-80	5.9	20
61	Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 4907-13	5.9	28
60	Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective study. <i>European Respiratory Journal</i> , 2015 , 46, 1205-7	13.6	37
59	The performance of five different dried blood spot cards for the analysis of six immunosuppressants. <i>Bioanalysis</i> , 2015 , 7, 1225-35	2.1	24
58	Role of therapeutic drug monitoring in pulmonary infections: use and potential for expanded use of dried blood spot samples. <i>Bioanalysis</i> , 2015 , 7, 481-95	2.1	17
57	The Never Ending Struggle Against Development of Drug Resistance. <i>Clinical Infectious Diseases</i> , 2015 , 61, 137-8	11.6	
56	Adequate design of pharmacokinetic-pharmacodynamic studies will help optimize tuberculosis treatment for the future. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 2474	5.9	6
55	Limited sampling strategies for therapeutic drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosis. <i>International Journal of Antimicrobial Agents</i> , 2015 , 46, 332-7	14.3	26
54	The relation of the number of hydrogen-bond acceptors with recoveries of immunosuppressants in DBS analysis. <i>Bioanalysis</i> , 2015 , 7, 1717-22	2.1	8
53	Subtherapeutic Posaconazole Exposure and Treatment Outcome in Patients With Invasive Fungal Disease. <i>Therapeutic Drug Monitoring</i> , 2015 , 37, 766-71	3.2	26
52	What is the right blood hematocrit preparation procedure for standards and quality control samples for dried blood spot analysis?. <i>Bioanalysis</i> , 2015 , 7, 345-51	2.1	41
51	Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis. <i>European Respiratory Journal</i> , 2015 , 46, 444-55	13.6	13
50	Therapeutic drug monitoring: how to improve drug dosage and patient safety in tuberculosis treatment. <i>International Journal of Infectious Diseases</i> , 2015 , 32, 101-4	10.5	28

49	The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection. <i>European Respiratory Journal</i> , 2015 , 45, 569-71	13.6	18
48	Quantification of co-trimoxazole in serum and plasma using MS/MS. <i>Bioanalysis</i> , 2015 , 7, 2741-9	2.1	2
47	An interlaboratory quality control programme for the measurement of tuberculosis drugs. <i>European Respiratory Journal</i> , 2015 , 46, 268-71	13.6	20
46	Limited-sampling strategies for anidulafungin in critically ill patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 1177-81	5.9	8
45	Quantification of isoniazid, pyrazinamide and ethambutol in serum using liquid chromatography-tandem mass spectrometry. <i>Journal of Applied Bioanalysis</i> , 2015 , 1, 89-98	1.3	12
44	Simultaneous determination of rifampicin, clarithromycin and their metabolites in dried blood spots using LC-MS/MS. <i>Talanta</i> , 2014 , 121, 9-17	6.2	52
43	Inflammation is associated with voriconazole trough concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 7098-101	5.9	59
42	Insufficient fluconazole exposure in pediatric cancer patients and the need for therapeutic drug monitoring in critically ill children. <i>Clinical Infectious Diseases</i> , 2014 , 59, 1527-33	11.6	22
41	Raltegravir and rifampicin in patients with HIV and tuberculosis. <i>Lancet Infectious Diseases</i> , 2014 , 14, 1046-1047	25.5	2
40	Quantification and validation of ertapenem using a liquid chromatography-tandem mass spectrometry method. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 3481-4	5.9	10
39	In vitro synergy between linezolid and clarithromycin against Mycobacterium tuberculosis. <i>European Respiratory Journal</i> , 2014 , 44, 808-11	13.6	10
38	Five year results of an international proficiency testing programme for measurement of antifungal drug concentrations. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 2988-94	5.1	23
37	Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2014 , 43, 884-97	13.6	45
36	Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin. <i>International Journal of Antimicrobial Agents</i> , 2014 , 44, 229-34	14.3	51
35	Quantification of amikacin and kanamycin in serum using a simple and validated LC-MS/MS method. <i>Bioanalysis</i> , 2014 , 6, 2125-33	2.1	24
34	Clinical validation of the analysis of fluconazole in oral fluid in hospitalized children. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 6742-6	5.9	9
33	Low but sufficient anidulafungin exposure in critically ill patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 304-8	5.9	21
32	Trimethoprim/sulfamethoxazole susceptibility of Mycobacterium tuberculosis. <i>International Journal of Antimicrobial Agents</i> , 2013 , 42, 472-4	14.3	14

31	Troubleshooting carry-over of LC-MS/MS method for rifampicin, clarithromycin and metabolites in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013 , 917-918, 1-4	3.2	26
30	Fast LC-MS/MS analysis of tacrolimus, sirolimus, everolimus and cyclosporin A in dried blood spots and the influence of the hematocrit and immunosuppressant concentration on recovery. <i>Talanta</i> , 2013 , 115, 47-54	6.2	86
29	Simultaneous quantification of anidulafungin and caspofungin in plasma by an accurate and simple liquid chromatography tandem mass-spectrometric method. <i>Therapeutic Drug Monitoring</i> , 2013 , 35, 778-84	3.2	13
28	Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2013 , 42, 504-12	13.6	43
27	Dried blood spot analysis suitable for therapeutic drug monitoring of voriconazole, fluconazole, and posaconazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 4999-5004	5.9	43
26	Drug concentration in lung tissue in multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2013 , 42, 1750-2	13.6	17
25	Clinical validation of the analysis of linezolid and clarithromycin in oral fluid of patients with multidrug-resistant tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 3676-80	5.9	18
24	Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients. <i>European Respiratory Journal</i> , 2013 , 42, 1614-21	13.6	49
23	Plasma concentrations of caspofungin at two different dosage regimens in a patient with hepatic dysfunction. <i>Transplant Infectious Disease</i> , 2012 , 14, 440-3	2.7	13
22	Dried blood spot analysis combined with limited sampling models can advance therapeutic drug monitoring of tuberculosis drugs. <i>Journal of Infectious Diseases</i> , 2012 , 205, 1765-6; author reply 1766	7	12
21	Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 5758-63	5.9	57
20	Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis. <i>Therapeutic Drug Monitoring</i> , 2011 , 33, 350-4	3.2	27
19	Determination of moxifloxacin in dried blood spots using LC-MS/MS and the impact of the hematocrit and blood volume. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2011 , 879, 1063-70	3.2	98
18	Dried blood spots: a new tool for tuberculosis treatment optimization. <i>Current Pharmaceutical Design</i> , 2011 , 17, 2931-9	3.3	58
17	Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 1287-9	5.9	50
16	Fluoroquinolones, the cornerstone of treatment of drug-resistant tuberculosis: a pharmacokinetic and pharmacodynamic approach. <i>Current Pharmaceutical Design</i> , 2011 , 17, 2900-30	3.3	21
15	Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience. <i>European Respiratory Journal</i> , 2011 , 38, 888-94	13.6	58
14	Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 3878-83	5.9	43

13	Clarithromycin significantly increases linezolid serum concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 5418-9	5.9	24
12	Determination of moxifloxacin in human plasma, plasma ultrafiltrate, and cerebrospinal fluid by a rapid and simple liquid chromatography- tandem mass spectrometry method. <i>Journal of Analytical Toxicology</i> , 2010 , 34, 135-41	2.9	44
11	Intravenous voriconazole after toxic oral administration. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 2741-2	5.9	9
10	Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients. <i>Clinical Pharmacokinetics</i> , 2010 , 49, 559-65	6.2	39
9	Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 97-101	3.2	48
8	Method for therapeutic drug monitoring of azole antifungal drugs in human serum using LC/MS/MS. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010 , 878, 39-44	3.2	77
7	Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis. <i>Clinical Infectious Diseases</i> , 2009 , 49, 1080-2	11.6	83
6	Omeprazole significantly reduces posaconazole serum trough level. <i>Clinical Infectious Diseases</i> , 2009 , 48, 839	11.6	44
5	High voriconazole trough levels in relation to hepatic function: how to adjust the dosage?. <i>British Journal of Clinical Pharmacology</i> , 2009 , 67, 262-3	3.8	20
4	Simultaneous determination of clarithromycin, rifampicin and their main metabolites in human plasma by liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009 , 877, 1771-7	3.2	42
3	Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. <i>Clinical Infectious Diseases</i> , 2009 , 48, 1441-58	11.6	300
2	Ethambutol-induced optical neuropathy: risk of overdosing in obese subjects. <i>International Journal of Tuberculosis and Lung Disease</i> , 2008 , 12, 967-71	2.1	13
1	Monitoring during and after tuberculosis treatment308-325		1